Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , appears to represent a promising step forward for body loss . Early clinical trials have shown considerable decreases in body tissue, conceivably exceeding current body composition medications . However , additio